Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 19/20 | 0.60 |
| ▸ | MAP4K1 | Q92918 | 10/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22263024 | 0.89 | KLKB1 (0.62) | KLKB1MAP4K1 | |
| SCHEMBL19780336 | 0.87 | KLKB1 (0.58) | KLKB1MAP4K1 | |
| SCHEMBL19779880 | 0.81 | KLKB1 (0.50) | KLKB1MAP4K1 | |
| SCHEMBL21177641 | 0.79 | KLKB1 (0.48) | KLKB1MAP4K1 | |
| SCHEMBL19780293 | 0.79 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL21177282 | 0.78 | KLKB1 (0.55) | KLKB1MAP4K1 | |
| SCHEMBL19780332 | 0.77 | KLKB1 (0.47) | KLKB1MAP4K1 | |
| SCHEMBL19779884 | 0.76 | KLKB1 (1.00) | KLKB1MAP4K1 | |
| SCHEMBL19780371 | 0.76 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL22426101 | 0.76 | KLKB1 (0.46) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| CN-110022875-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-07-16 | — | — | CN | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885PTGER1 279/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885PTGER1 279/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885PTGER1 279/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885PTGER1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.